ADMA Biologics, Inc.
NASDAQ:ADMA
17.4 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | ADMA Biologics, Inc. |
Symbool | ADMA |
Munteenheid | USD |
Prijs | 17.4 |
Beurswaarde | 4,113,186,000 |
Dividendpercentage | 0% |
52-weken bereik | 4.16 - 23.64 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Adam S. Grossman |
Website | https://www.admabiologics.com |
An error occurred while fetching data.
Over ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)